FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083707930> ?p ?o ?g. }

• W3083707930 abstract "Engineered T cell therapies have been remarkably successful in the treatment of B cell malignancies, yet lack of control over these “living drugs” can lead to significant toxicities or limited efficacy. One particular challenge is the achievement of durable anti-tumor responses because the reduction of tumor burden results in reduced antigen stimulation and therefore reduced antigen-dependent T cell expansion. Interleukin-15 (IL15) drives T and NK cell expansion and persistence in an antigen-independent manner, however unregulated expression of this cytokine may compromise the safety and efficacy of cellular immunotherapy. To address these issues, we engineered T cells with a pharmacologically controllable, membrane-bound IL15 that supports antigen-independent T cell expansion and has the potential to reduce the safety risks associated with continuous exposure to soluble IL15. Our approach utilizes Drug Responsive Domains (DRDs) which are fully human protein domains that are inherently unstable in the cell but are reversibly stabilized when bound to specific FDA-approved drugs. Fusion of a DRD to a protein of interest confers drug-dependent, reversible regulation of protein expression and function. We developed a DRD based on the carbonic anhydrase 2 (CA2) protein, which is stabilized in the presence of the FDA-approved drug acetazolamide (ACZ). Upon gene transfer of membrane-bound IL15 fused to a CA2 DRD, regulated IL15 expression on T cells was detected only in the presence of ACZ. In the absence of ACZ, the level of IL15 detected on the surface of gene-modified T cells is not substantially different from the level detected on untransduced T cells. ACZ treatment of gene-modified T cells increases surface IL15 expression in a dose-dependent manner. We observed prolonged survival and up to 15-fold expansion of IL15-CA2 DRD-transduced T cells in the absence of supplemental cytokines or antigen stimulation. In contrast, vehicle-treated IL15-CA2 DRD modified T cells and untransduced T cells did not survive or expand in vitro. Importantly, both IL15-CA2-transduced T cells and unengineered, co-infused NK cells survived and persisted significantly more in vivo in ACZ-treated but not vehicle-treated non-tumor-bearing NSG mice. Our results demonstrate that a novel membrane-bound IL15-CA2 fusion protein coupled with ACZ treatment induces antigen-independent T cell expansion and augments bystander NK cell persistence. Regulatable IL15 expression has significant implications for both T and NK cell therapies by providing more durable cell expansion and cytolytic activity in vivo, and thus the potential to significantly reduce cell dosing while maintaining clinical efficacy in patients. Citation Format: Steven Shamah, Kutlu Elpek, Tucker Ezell, Michelle Fleury, Michael Gallo, Jennifer Gori, Scott Heller, Mara Inniss, Meghan Langley, Grace Olinger, Celeste Richardson, Karen Tran, Dhruv Sethi, Dexue Sun, Vipin Suri. Drug responsive domain regulation of IL15-engineered T cells provides pharmacological control over antigen-independent cell expansion [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6604." @default.
• W3083707930 created "2020-09-11" @default.
• W3083707930 creator A5023944186 @default.
• W3083707930 creator A5027746837 @default.
• W3083707930 creator A5031525373 @default.
• W3083707930 creator A5037171638 @default.
• W3083707930 creator A5038857529 @default.
• W3083707930 creator A5041312424 @default.
• W3083707930 creator A5044326403 @default.
• W3083707930 creator A5052467999 @default.
• W3083707930 creator A5057801127 @default.
• W3083707930 creator A5066299057 @default.
• W3083707930 creator A5067979266 @default.
• W3083707930 creator A5068499852 @default.
• W3083707930 creator A5079577338 @default.
• W3083707930 creator A5087525727 @default.
• W3083707930 creator A5089568647 @default.
• W3083707930 date "2020-08-13" @default.
• W3083707930 modified "2023-09-25" @default.
• W3083707930 title "Abstract 6604: Drug responsive domain regulation of IL15-engineered T cells provides pharmacological control over antigen-independent cell expansion" @default.
• W3083707930 doi "https://doi.org/10.1158/1538-7445.am2020-6604" @default.
• W3083707930 hasPublicationYear "2020" @default.
• W3083707930 type Work @default.
• W3083707930 sameAs 3083707930 @default.
• W3083707930 citedByCount "0" @default.
• W3083707930 crossrefType "proceedings-article" @default.
• W3083707930 hasAuthorship W3083707930A5023944186 @default.
• W3083707930 hasAuthorship W3083707930A5027746837 @default.
• W3083707930 hasAuthorship W3083707930A5031525373 @default.
• W3083707930 hasAuthorship W3083707930A5037171638 @default.
• W3083707930 hasAuthorship W3083707930A5038857529 @default.
• W3083707930 hasAuthorship W3083707930A5041312424 @default.
• W3083707930 hasAuthorship W3083707930A5044326403 @default.
• W3083707930 hasAuthorship W3083707930A5052467999 @default.
• W3083707930 hasAuthorship W3083707930A5057801127 @default.
• W3083707930 hasAuthorship W3083707930A5066299057 @default.
• W3083707930 hasAuthorship W3083707930A5067979266 @default.
• W3083707930 hasAuthorship W3083707930A5068499852 @default.
• W3083707930 hasAuthorship W3083707930A5079577338 @default.
• W3083707930 hasAuthorship W3083707930A5087525727 @default.
• W3083707930 hasAuthorship W3083707930A5089568647 @default.
• W3083707930 hasConcept C126322002 @default.
• W3083707930 hasConcept C147483822 @default.
• W3083707930 hasConcept C1491633281 @default.
• W3083707930 hasConcept C154317977 @default.
• W3083707930 hasConcept C185592680 @default.
• W3083707930 hasConcept C202751555 @default.
• W3083707930 hasConcept C203014093 @default.
• W3083707930 hasConcept C2776090121 @default.
• W3083707930 hasConcept C2777371288 @default.
• W3083707930 hasConcept C2777405951 @default.
• W3083707930 hasConcept C2777701055 @default.
• W3083707930 hasConcept C2778690821 @default.
• W3083707930 hasConcept C55493867 @default.
• W3083707930 hasConcept C62112901 @default.
• W3083707930 hasConcept C71924100 @default.
• W3083707930 hasConcept C86803240 @default.
• W3083707930 hasConcept C8891405 @default.
• W3083707930 hasConcept C95444343 @default.
• W3083707930 hasConcept C98274493 @default.
• W3083707930 hasConceptScore W3083707930C126322002 @default.
• W3083707930 hasConceptScore W3083707930C147483822 @default.
• W3083707930 hasConceptScore W3083707930C1491633281 @default.
• W3083707930 hasConceptScore W3083707930C154317977 @default.
• W3083707930 hasConceptScore W3083707930C185592680 @default.
• W3083707930 hasConceptScore W3083707930C202751555 @default.
• W3083707930 hasConceptScore W3083707930C203014093 @default.
• W3083707930 hasConceptScore W3083707930C2776090121 @default.
• W3083707930 hasConceptScore W3083707930C2777371288 @default.
• W3083707930 hasConceptScore W3083707930C2777405951 @default.
• W3083707930 hasConceptScore W3083707930C2777701055 @default.
• W3083707930 hasConceptScore W3083707930C2778690821 @default.
• W3083707930 hasConceptScore W3083707930C55493867 @default.
• W3083707930 hasConceptScore W3083707930C62112901 @default.
• W3083707930 hasConceptScore W3083707930C71924100 @default.
• W3083707930 hasConceptScore W3083707930C86803240 @default.
• W3083707930 hasConceptScore W3083707930C8891405 @default.
• W3083707930 hasConceptScore W3083707930C95444343 @default.
• W3083707930 hasConceptScore W3083707930C98274493 @default.
• W3083707930 hasLocation W30837079301 @default.
• W3083707930 hasOpenAccess W3083707930 @default.
• W3083707930 hasPrimaryLocation W30837079301 @default.
• W3083707930 hasRelatedWork W12161941 @default.
• W3083707930 hasRelatedWork W12333971 @default.
• W3083707930 hasRelatedWork W20133129 @default.
• W3083707930 hasRelatedWork W2151330 @default.
• W3083707930 hasRelatedWork W424612 @default.
• W3083707930 hasRelatedWork W5331139 @default.
• W3083707930 hasRelatedWork W6758712 @default.
• W3083707930 hasRelatedWork W6837732 @default.
• W3083707930 hasRelatedWork W7380066 @default.
• W3083707930 hasRelatedWork W7825645 @default.
• W3083707930 isParatext "false" @default.
• W3083707930 isRetracted "false" @default.
• W3083707930 magId "3083707930" @default.
• W3083707930 workType "article" @default.